Partners & Collaborators

The following profiles illustrate our strength and breadth of capability and collaboration, with promising implications for improved patient treatments and outcomes:

Partners

Eye & Vision Science Group

The Eye and Vision Science Group is a partnership between the Department of Eye and Vision Science and St. Paul’s Eye Unit, RLBUHT studying the mechanisms, prevention, early detection and treatment of eye diseases. Clinical and non-clinical researchers, from a range of scientific backgrounds, work closely together on translational research for the benefit of patients.

Department of Eye & Vision Science
  • Basic, applied and clinical research from basic molecular interactions through to health service implementation
  • Internal partnerships in Liverpool across engineering and biological sciences, orthoptics and vision science, mathematics, psychology
  • Biotechnology collaborations with NHS Blood & Transplant, development companies and the pharmaceutical industry in product development
  • Collaboration within & outside the University both nationally & internationally
  • Key researchers: Professors Simon Harding, Ian Grierson, Paul Hiscott, David Wong and Stephen Kaye, Drs Rachel Williams, Paul Knox, Luminita Paraoan and Carl Sheridan
Directorate of Opthalmology
  • Research focused specialist services including: Ocular Oncology (Professor Heinrich Heimann), Cornea (Stephen Kaye), Surgical retina (Theodor Stappler), Medical retina (Jayashree Nair Sahni, Heimann), Glaucoma (Anshoo Choudhary)
  • Actively developing new diagnoses & treatments
Clinical Eye Research Centre
  • A purpose built centre underpins the translational research theme creating a clear pathway from 'bench to bedside'
  • Diagnostic technologies, grading & assessment, new treatment modalities, consequences of new therapeutic regimes on disease mechanisms
  • The Trust’s Medical Physics & Clinical Engineering supports clinical and research ophthalmology
Selection of Collaborative Research Opportunities
  • Image Analysis & application to early detection of eye disease (Ophthalmology Reading Centre with trained graders, computer scientists, engineers & mathematicians)
  • Stem Cell & Cell Based Therapies – new technologies for advanced eye treatments (biologists & engineers)
  • Molecular & Cell Biology (range of diseases)
  • Biomarkers (electrophysiology, high end eye imaging)
  • Psychophysics & Eye Movement
  • Clinical Trials
  • Health Services Research
  • Tropical Diseases
International Partnerships
  • Department of Ophthalmology, University of Hong Kong partnership, joint appointment of Professor David Wong
  • IOBA, University of Valladolid, Spain, partner translational research group - Professor Carlos Pastor
  • University of Malawi, Blantyre (Malawi-Liverpool-Wellcome Research Centre). Disease (Malaria, Diabetes)
  • Universities of North Texas and of Gainesville, USA and University of Erlangen-Nurnberg, Germany
Commercial Partnerships
  • Novartis/Alcon (Glaucoma therapeutics)
  • Agepha (Nutrition in Age-related Macular Degeneration)
  • Abbott (Corneal therapeutics)
  • Fluoron GMbH (Development of emulsification resistance tamponade agent)
  • Pfizer – Faculty leads to EYECAMPUS (Harding, Stephenson): rapidly expanding UK interdisciplinary educational initiative

Infectious Diseases, including HIV

Liverpool has an international reputation in the fields of drug safety research & personalised medicines. The common theme is new approaches that maximise the benefits of existing drug therapies.

Biomedical Research Centre Microbial Diseases
  • The Trust, with its partners University of Liverpool & LSTM, awarded a NIHR BRC by the Department of Health - one of only twelve in country
  • Emphasis on translational research – taking advances in basic medical research out of the laboratory and through commercial partnerships into the clinical setting
  • Current projects include a new test for the early diagnosis of sepsis, an innovative plantain extract (see case study on Provexis) treatment for Crohn’s disease, and a new TB drug therapy developed at the LSTM
  • Improving effectiveness of HIV therapy including a project to tailor treatment to individual patients
  • Collaboration with commercial partners
  • Largest research programme of its kind in the UK
  • Aim to define mechanisms of variability in drug response & translate findings into clinical care
  • Wolfson Centre, funded by UoL & a £2million donation from the Wolfson Foundation opened in 2009
  • Collaboration with researchers locally, regionally, nationally and internationally
Nanotechnology for Drug Delivery
  • Developing techniques for using nanoparticles in drug delivery
  • Focus on HIV, in conjunction with Dr Andrew Owen (Department of Pharmacology) & Professor Saye Khoo (Pharmacology & RLUH infectious diseases team)
  • Collaboration with IOTA NanoSolutions based in the MerseyBIO incubator (managed by 2Bio Ltd)
MRC Centre for Drug Safety
  • Joint venture Universities of Liverpool & Manchester
  • Critical mass of knowledge & technologies
  • Advance understanding of adverse drug reactions
  • Strong links to the Medicines and Healthcare products Regulatory Agency (MHRA) with Professor Munir Pirmohamed and Professor Kevin Park being Commissioners on Human Medicines
  • Collaboration between researchers, industry & regulatory bodies
Commercial Partnerships
  • Glaxo Smith Kline
  • Merck Sharp & Dohme
  • Astra Zeneca
  • Novartis
  • Pfizer
Email this page Print this page